Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8268791 | UPSHER SMITH LABS | Alkylglycoside compositions for drug administration |
May, 2026
(3 years from now) | |
US8440631 | UPSHER SMITH LABS | Compositions for drug administration |
May, 2026
(3 years from now) | |
US9283280 | UPSHER SMITH LABS | Compositions for drug administration |
May, 2026
(3 years from now) | |
US11337962 | UPSHER SMITH LABS | Formulations comprising triptan compounds |
Jun, 2030
(7 years from now) | |
US9974770 | UPSHER SMITH LABS | Formulations comprising triptan compounds |
Jun, 2030
(7 years from now) | |
US9610280 | UPSHER SMITH LABS | Formulations comprising triptan compounds |
Jun, 2030
(7 years from now) | |
US10603305 | UPSHER SMITH LABS | Formulations comprising triptan compounds |
Jun, 2030
(7 years from now) | |
US9211282 | UPSHER SMITH LABS | Formulations comprising triptan compounds |
Jul, 2031
(8 years from now) |
Market Authorisation Date: 25 January, 2019
Treatment: Acute treatment of migraine
Dosage: SPRAY;NASAL
56
United States
7
European Union
5
Australia
5
Japan
4
Russia
4
Korea, Republic of
4
China
4
Canada
3
Brazil
3
Spain
3
United Kingdom
2
Denmark
2
Mexico
2
India
2
New Zealand
1
Israel
1
South Africa
1
IB
1
Hong Kong
1
Morocco
1
Germany
1
Singapore
1
EA
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic